BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35105861)

  • 21. Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
    Martinikova AS; Burocziova M; Stoyanov M; Macurek L
    Cells; 2020 Sep; 9(9):. PubMed ID: 32927737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein phosphatase, Mg
    Husby S; Hjermind Justesen E; Grønbæk K
    Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Kahn JD; Miller PG; Silver AJ; Sellar RS; Bhatt S; Gibson C; McConkey M; Adams D; Mar B; Mertins P; Fereshetian S; Krug K; Zhu H; Letai A; Carr SA; Doench J; Jaiswal S; Ebert BL
    Blood; 2018 Sep; 132(11):1095-1105. PubMed ID: 29954749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
    Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
    Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
    Uyanik B; Goloudina AR; Akbarali A; Grigorash BB; Petukhov AV; Singhal S; Eruslanov E; Chaloyard J; Lagorgette L; Hadi T; Baidyuk EV; Sakai H; Tessarollo L; Ryffel B; Mazur SJ; Lirussi F; Garrido C; Appella E; Demidov ON
    Nat Commun; 2021 Jun; 12(1):3622. PubMed ID: 34131120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
    Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
    Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
    Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
    J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
    Hsu JI; Dayaram T; Tovy A; De Braekeleer E; Jeong M; Wang F; Zhang J; Heffernan TP; Gera S; Kovacs JJ; Marszalek JR; Bristow C; Yan Y; Garcia-Manero G; Kantarjian H; Vassiliou G; Futreal PA; Donehower LA; Takahashi K; Goodell MA
    Cell Stem Cell; 2018 Nov; 23(5):700-713.e6. PubMed ID: 30388424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
    Wang P; Ye JA; Hou CX; Zhou D; Zhan SQ
    Oncol Rep; 2016 Nov; 36(5):2544-2552. PubMed ID: 27633132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    Kim B; Won D; Lee ST; Choi JR
    PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPM1D activity promotes the replication stress caused by cyclin E1 overexpression.
    Martinikova AS; Stoyanov M; Oravetzova A; Kok YP; Yu S; Dobrovolna J; Janscak P; van Vugt M; Macurek L
    Mol Oncol; 2024 Jan; 18(1):6-20. PubMed ID: 37067201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fortifying p53 - beyond Mdm2 inhibitors.
    Sriraman A; Li Y; Dobbelstein M
    Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
    [No Abstract]   [Full Text] [Related]  

  • 36. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.
    Dubois FPB; Shapira O; Greenwald NF; Zack T; Wala J; Tsai JW; Crane A; Baguette A; Hadjadj D; Harutyunyan AS; Kumar KH; Blattner-Johnson M; Vogelzang J; Sousa C; Kang KS; Sinai C; Wang DK; Khadka P; Lewis K; Nguyen L; Malkin H; Ho P; O'Rourke R; Zhang S; Gold R; Deng D; Serrano J; Snuderl M; Jones C; Wright KD; Chi SN; Grill J; Kleinman CL; Goumnerova LC; Jabado N; Jones DTW; Kieran MW; Ligon KL; Beroukhim R; Bandopadhayay P
    Nat Cancer; 2022 Aug; 3(8):994-1011. PubMed ID: 35788723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.
    Mackay A; Burford A; Carvalho D; Izquierdo E; Fazal-Salom J; Taylor KR; Bjerke L; Clarke M; Vinci M; Nandhabalan M; Temelso S; Popov S; Molinari V; Raman P; Waanders AJ; Han HJ; Gupta S; Marshall L; Zacharoulis S; Vaidya S; Mandeville HC; Bridges LR; Martin AJ; Al-Sarraj S; Chandler C; Ng HK; Li X; Mu K; Trabelsi S; Brahim DH; Kisljakov AN; Konovalov DM; Moore AS; Carcaboso AM; Sunol M; de Torres C; Cruz O; Mora J; Shats LI; Stavale JN; Bidinotto LT; Reis RM; Entz-Werle N; Farrell M; Cryan J; Crimmins D; Caird J; Pears J; Monje M; Debily MA; Castel D; Grill J; Hawkins C; Nikbakht H; Jabado N; Baker SJ; Pfister SM; Jones DTW; Fouladi M; von Bueren AO; Baudis M; Resnick A; Jones C
    Cancer Cell; 2017 Oct; 32(4):520-537.e5. PubMed ID: 28966033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
    Lu X; Nannenga B; Donehower LA
    Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
    Zhang L; Hsu JI; Goodell MA
    Mol Cancer Res; 2022 Sep; 20(9):1365-1378. PubMed ID: 35657598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.